Clinical Trials Logo

Clinical Trial Summary

This phase I trial studies how well cemiplimab before and after surgery works in treating patients with high risk cutaneous squamous cell cancer. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cemiplimab before surgery may improve risk of the cancer returning in patients with high risk cutaneous squamous cell cancer.


Clinical Trial Description

PRIMARY OBJECTIVE: I. To establish the pathologic response rate of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma (cSCC). SECONDARY OBJECTIVES: I. To document the local recurrence rate of high-risk cSCC treated with adjuvant cemiplimab. II. To document the systemic recurrence rate of high-risk cSCC treated with adjuvant cemiplimab. III. To document the 6-month, 12-month, 2-year overall survival (OS), recurrence-free survival (RFS) for patients with high risk cSCC. TERTIARY/EXPLORATORY OBJECTIVE: I. To evaluate the immune profile of fresh tumor tissue, blood in patients with cSCC treated with cemiplimab. OUTLINE: NEOADJUVANT PHASE: Prior to standard of care surgery, patients receive cemiplimab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity. ADJUVANT PHASE: Within 2-6 weeks after completion of standard of care radiation therapy (or surgery if no radiation therapy), patients receive cemiplimab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 18 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 12 weeks for 2 years, every 6 months for the next 3 years, and then annually for up to 10 years. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04428671
Study type Interventional
Source Emory University
Contact Michael Lowe, MD
Phone 404-778-6351
Email mlowe3@emory.edu
Status Recruiting
Phase Phase 1
Start date May 15, 2020
Completion date October 1, 2030

See also
  Status Clinical Trial Phase
Active, not recruiting NCT03816332 - Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Phase 1
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Completed NCT01198028 - Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT04163952 - Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin Phase 1
Active, not recruiting NCT02721732 - Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Phase 2
Recruiting NCT05896839 - Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Phase 1/Phase 2
Completed NCT03108131 - Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Phase 2